Boston Scientific’s stock surged 40.6% in the past year, far outpacing the broader market. This growth stems from strong ...

Boston Scientific’s BSX fourth-quarter 2024 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive strategic ...

The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say ...

Boston Scientific (NYSE:BSX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a ...

In a wide manufacturing room with white walls and low ceilings, Boston Scientific employees combine components into finished ...

The global Bioabsorbable Stents Market, valued at US$ 375.5 million in 2022, is expected to grow at a compound annual growth ...

The intracranial stents market is experiencing rapid growth, fueled by the rising incidence of strokes, aneurysms, and ...

India Coronary Stents Market is estimated to be valued at US$ 1,303.5 million in 2023 and is expected to exhibit a CAGR of 13.2 % by (2023-2030). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...

Boston Scientific Corporation ( NYSE: BSX) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Officer Art Butcher - ...

Gastrointestinal Stents Market. The global gastrointestinal stents market is experiencing robust growth, with the latest industry analysis projecting it to reach USD 815.34 millio ...

Boston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025.

StockNews.com upgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Friday. A number of other equities analysts ...